Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

Clinical trial NCT00621049 · COMPLETED

Trial details

NCT number: NCT00621049
Sponsor: SCRI Development Innovations, LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2007-12-01
Primary completion: 2013-07-01
Enrollment: 112

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.